Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CareDx, Inc. - Common Stock (NQ:CDNA)

20.55 +0.36 (+1.78%)
Streaming Delayed Price Updated: 3:45 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CareDx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings
From CareDx, Inc.
Via Business Wire
News headline image
CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026 ↗
The CEO of this leading medical diagnostic company sold shares throughout multiple days in January. But the manner in which the shares were sold shouldn't concern investors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
CareDx President and CEO Sells 19,000 Shares for $412,000 ↗
This transplant diagnostics specialist saw a notable insider sale amid a year of modest share price decline and ongoing product innovation. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
4 Analysts Assess CareDx: What You Need To Know ↗
 
Via Benzinga
News headline image
CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
From CareDx, Inc.
Via Business Wire
News headline image
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Provides Notice of Proposed Derivative Settlement
From CareDx, Inc.
Via Business Wire
News headline image
SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation
From CareDx, Inc.
Via Business Wire
News headline image
CareDx to Participate in Upcoming Investor Conferences
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025
From CareDx, Inc.
Via Business Wire
News headline image
3 Analysts Have This To Say About CareDx ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
What's going on in today's after hours session ↗
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
CareDx Announces Third Quarter 2025 Financial Results
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart Failure
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors
From CareDx, Inc.
Via Business Wire
News headline image
CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Issues Comment Letter on Draft LCD Policy
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential ↗
CareDx, Inc. faces uncertainty with proposed reimbursement changes, but has long-term potential in the $8 billion transplant solutions market. 
Via Benzinga
News headline image
This Actuate Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
CareDx to Participate in Wells Fargo Healthcare Conference
From CareDx, Inc.
Via Business Wire
News headline image
CareDx (CDNA) EPS Beats Sales Gain 14% ↗
Via The Motley Fool
News headline image
CareDx Inc (NASDAQ:CDNA) Posts Mixed Q2 2025 Results Amid Revenue Adjustments and Testing Growth ↗
CareDx Inc (CDNA) reported mixed Q2 2025 results with revenue of $86.7M, missing estimates, but adjusted revenue rose 14% YoY. Testing volumes grew 13%, while shares fell 6.8% post-earnings. 
Via Chartmill
News headline image
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer
From CareDx, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.